Sökning: onr:"swepub:oai:DiVA.org:uu-21443" >
Tropisetron (Navoba...
Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience
-
Sorbe, Bengt (författare)
-
Andersson, Håkan (författare)
-
Schmidt, Margareta (författare)
-
visa fler...
-
Söderberg, Martin (författare)
-
Högberg, Thomas (författare)
-
Wernstedt, Lars (författare)
-
- Tiensuu Janson, Eva (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
Ehrnström, Bengt (författare)
-
Kjaer, Mogens (författare)
-
Havsteen, Hanne (författare)
-
visa färre...
-
(creator_code:org_t)
- 1994
- 1994
- Engelska.
-
Ingår i: Supportive Care in Cancer. - 0941-4355 .- 1433-7339. ; 2:6, s. 393-399
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- An open, noncomparative, Nordic multicenter study was carried out during 1991-1992 to evaluate the 5-HT3 receptor antagonist tropisetron (Navoban) as an antiemetic agent for various types of cancer chemotherapy. A total of 630 patients were recruited from 15 centers in Sweden, Denmark, and Finland. Gynecological cancers (60%), breast cancer (15%), and lung cancer (10%) were the main diagnoses. Prior experience of chemotherapy was documented in 338 patients (54%). In 260 patients (41%), cisplatin was part of the cytostatic regimen. Carboplatin (23%), doxorubicin (27%), and epidoxorubicin (24%) were also frequently included. In all, 23 cytostatic agents were used in various combinations. The mean number of courses studied was 4.6 (range 1-19). Altogether, 394 of 619 evaluable patients (64%) were completely protected from acute nausea and vomiting during the first course of chemotherapy. Delayed nausea and vomiting were completely prevented in 45%-73% (days 2-6) in the complete series. Treatment efficacy remained stable (60%-79%) during ten consecutive courses of chemotherapy. With noncisplatin regimens, complete protection from acute nausea and vomiting was achieved in 72% compared with 52% for cisplatin regimens (P < 0.0001). Patients without prior experience of chemotherapy had higher control rates of acute nausea and vomiting (72%) compared to patients treated before (57%) during the first course, but not later on. There were no differences in delayed nausea and vomiting.
Nyckelord
- Adult
- Aged
- Aged; 80 and over
- Antiemetics/adverse effects/*therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/*adverse effects
- Female
- Finland
- Humans
- Indoles/adverse effects/*therapeutic use
- Male
- Middle Aged
- Nausea/chemically induced/*prevention & control
- Neoplasms/drug therapy
- Scandinavia
- Sex Factors
- Treatment Outcome
- Vomiting/chemically induced/*prevention & control
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sorbe, Bengt
-
Andersson, Håkan
-
Schmidt, Margare ...
-
Söderberg, Marti ...
-
Högberg, Thomas
-
Wernstedt, Lars
-
visa fler...
-
Tiensuu Janson, ...
-
Ehrnström, Bengt
-
Kjaer, Mogens
-
Havsteen, Hanne
-
visa färre...
- Artiklar i publikationen
-
Supportive Care ...
- Av lärosätet
-
Uppsala universitet